Zhang Lilong, Li Man, Cui Zhoujun, Chai Dongqi, Guan Yongjun, Chen Chen, Wang Weixing
Department of General Surgery, Renmin Hospital of Wuhan University, No. 238, Jiefang Road, Wuchang District, Wuhan, 430060, Hubei Province, China.
Central Laboratory, Renmin Hospital of Wuhan University, No. 238, Jiefang Road, Wuchang District, Wuhan, 430060, Hubei Province, China.
Cancer Cell Int. 2022 Jan 6;22(1):8. doi: 10.1186/s12935-021-02432-7.
In humans, riboflavin must be obtained through intestinal absorption because it cannot be synthesized by the body. SLC52A2 encodes a membrane protein belonging to the riboflavin transporter protein family and is associated with a variety of diseases. Here, we systematically explore its relevance to multiple human tumors.
We analyzed the association of SLC52A2 with 33 tumors using publicly available databases such as TCGA and GEO. We verified the SLC52A2 expression in hepatocellular carcinoma, gastric cancer, colon cancer, and rectal cancer using immunohistochemistry.
We report that SLC52A2 was highly expressed in almost all tumors, and the immunohistochemical results in the hepatocellular, gastric, colon, and rectal cancers were consistent with the above. SLC52A2 expression was linked to patient overall survival, disease-specific survival, progression-free interval, diagnosis, mutations, tumor mutational burden, microsatellite instability, common immune checkpoint genes, and immune cells infiltration. Enrichment analysis showed that SLC52A2 was mainly enriched in oocyte meiosis, eukaryotic ribosome biogenesis, and cell cycle. In hepatocellular carcinoma, the SLC52A2 expression is an independent prognostic factor. The SNHG3 and THUMPD3-AS1/hsa-miR-139-5p-SLC52A2 axis were identified as potential regulatory pathways in hepatocellular carcinoma.
In conclusion, we have systematically described for the first time that SLC52A2 is closely associated with a variety of tumors, especially hepatocellular carcinoma.
在人类中，核黄素必须通过肠道吸收获得，因为人体无法合成。SLC52A2编码一种属于核黄素转运蛋白家族的膜蛋白，与多种疾病相关。在此，我们系统地探讨其与多种人类肿瘤的相关性。
我们使用诸如TCGA和GEO等公开可用数据库分析SLC52A2与33种肿瘤的关联。我们通过免疫组织化学验证了SLC52A2在肝细胞癌、胃癌、结肠癌和直肠癌中的表达。
我们报告SLC52A2在几乎所有肿瘤中均高表达，肝细胞癌、胃癌、结肠癌和直肠癌的免疫组织化学结果与上述一致。SLC52A2表达与患者总生存期、疾病特异性生存期、无进展间期、诊断、突变、肿瘤突变负荷、微卫星不稳定性、常见免疫检查点基因和免疫细胞浸润相关。富集分析表明，SLC52A2主要富集于卵母细胞减数分裂、真核生物核糖体生物合成和细胞周期。在肝细胞癌中，SLC52A2表达是一个独立的预后因素。SNHG3和THUMPD3-AS1/hsa-miR-139-5p-SLC52A2轴被确定为肝细胞癌中的潜在调控途径。
总之，我们首次系统地描述了SLC52A2与多种肿瘤密切相关，尤其是肝细胞癌。
